Racura Oncology has treated the first patient in its phase 1 HARNESS‑1 clinical trial of RC220 for EGFR‑mutant non‑small cell ...

M42’s Insights Research Organization and Solutions has launched the UAE’s first genomics-driven clinical trial, working with the Department of Health – Abu Dhabi and Halia T ...

The European Commission has approved Sanofi’s Cenrifki (tolebrutinib) for adults with secondary progressive multiple ...

Agomab Therapeutics has announced the design of its phase 2b NOV‑ERA study of ontunisertib in fibrostenosing Crohn’s disease, ...

Company secures first commercial product with data for active and chronic TED Viridian Therapeutics has received US FDA approval for Lumvoa (veligrotug-vvze) for thyroid eye disease, marking the first ...

Lundbeck will present new migraine data at the European Academy of Neurology Congress 2026, taking place from 27–30 June in ...

First immunotherapy approved for LACC in England offers new treatment option for women MSD has welcomed the National Institute for Health and Care Excellence’s recommendation of pembrolizumab ...

When looking to treat erectile dysfunction, there are two commonly used treatment options available for patients. These are Viagra and sildenafil: two similar but distinct types of medication. Both ...

Breakwater phase 3 data show significant gains in progression‑free survival Laboratoires Pierre Fabre has secured European Commission approval for Braftovi (encorafenib) in combination with cetuximab ...

Compressed air is among the largest energy expenses in pharmaceutical manufacturing and must remain entirely contamination-free.

Sanofi has announced the launch of its high-dose egg-based quadrivalent influenza vaccine (QIV-HD) in the UK. This vaccine is designed for people aged 65 and older, as well as clinically at-risk ...

New funding will support the phase 2 expansion trial of THEO-260 The Oxford-based biotechnology company Theolytics has been awarded €8 million in non-dilutive grant funding from Horizon Europe 2025.